A5069152234- Cholangiocarcinoma and Gallbladder Cancer Studies
- Pancreatic and Hepatic Oncology Research
- Cancer Mechanisms and Therapy
- Colorectal Cancer Treatments and Studies
- Hematopoietic Stem Cell Transplantation
- MicroRNA in disease regulation
- Pediatric Hepatobiliary Diseases and Treatments
- Monoclonal and Polyclonal Antibodies Research
- Liver physiology and pathology
- Cell Adhesion Molecules Research
- Peptidase Inhibition and Analysis
- HER2/EGFR in Cancer Research
- Immune Cell Function and Interaction
- Mesenchymal stem cell research
- Chemokine receptors and signaling
- Sarcoma Diagnosis and Treatment
- Genetic factors in colorectal cancer
- Cancer-related molecular mechanisms research
- Hepatocellular Carcinoma Treatment and Prognosis
- Drug Transport and Resistance Mechanisms
- Lung Cancer Treatments and Mutations
- Erythrocyte Function and Pathophysiology
- Chemotherapy-induced cardiotoxicity and mitigation
- Phagocytosis and Immune Regulation
- Cancer Genomics and Diagnostics
Candiolo Cancer Institute
2013-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2021-2025
Hospital Santa Caterina
2014
University of Turin
2000-2012
Fondazione Piemontese per la Ricerca sul Cancro Onlus
2012
A. O. Ordine Mauriziano di Torino
1999-2009
Weizmann Institute of Science
1999
Amgen (United States)
1998
Osteosarcoma (OS) is the most common primary bone tumour in children and young adults. Despite improved prognosis, metastatic or relapsed OS remains largely incurable no significant improvement has been observed last 20 years. Therefore, search for alternative agents mandatory.We investigated phospho-ERK 1/2, MCL-1, phospho-Ezrin/Radixin/Moesin (P-ERM) as potential therapeutic targets OS. Activation of these pathways was shown by immunohistochemistry about 70% cases all cell lines analyzed....
Advanced biliary tract carcinomas (BTCs) have poor prognosis and limited therapeutic options. Therefore, it is crucial to combine standard therapies with molecular targeting. In this study EGFR, HER2, their transducers were analysed in terms of mutations, amplifications over-expression a BTC case series. Furthermore, we tested the efficacy drugs targeting these molecules, as single agents or combination gemcitabine, agent against BTC. Immunohistochemistry, FISH mutational analysis performed...
Abstract Objective: Conventional therapies are still unsuccessful in patients with carcinoma arising from the biliary tract. Somatic mutations of epidermal growth factor receptor (EGFR) gene and activation its downstream pathways predict sensitivity to small-molecule inhibitors non–small cell lung carcinoma. Therefore, we analyzed EGFR related gallbladder bile duct carcinomas consider possible application these alternative therapeutic strategies. Experimental Design: Forty paraffin-embedded...
Background/Objectives: Intrahepatic cholangiocarcinoma (iCCA) is a malignant liver tumor with rising global incidence and poor prognosis, largely due to late-stage diagnosis limited effective treatment options. Standard chemotherapy regimens, including cisplatin gemcitabine, often fail because of the development multidrug resistance (MDR), leaving patients few alternative therapies. Doxycycline, tetracycline antibiotic, has demonstrated antitumor effects across various cancers, influencing...
Abstract Despite intensive chemotherapy and surgery treatment, lung bone metastasis develop in about 30% of patients with osteosarcoma. Mechanisms for this preferential metastatic behavior are largely unknown. We investigated the role chemokine receptor 4 (CXCR4)/stromal cell–derived factor 1 (SDF-1) system to drive homing osteosarcoma cells. analyzed expression CXCR4 SDF-1 proteins on several cell lines effects migration, adhesion, proliferation these cancer In vitro assays showed that...
Activating mutations of the epidermal growth factor receptor (EGFR) confer sensitivity to tyrosine kinase inhibitors (TKi), gefitinib and erlotinib. We analysed EGFR expression, mutation status gene expression profiles prostate cancer (PC) supply a rationale for targeted therapies in this disease. Mutational analysis TK domain (exons from 18 21) immunohistochemistry were performed on tumour tissues derived radical prostatectomy 100 PC patients. Gene profiling using oligo-microarrays was also...
Intrahepatic cholangiocarcinoma (ICC) is an aggressive, highly lethal tumors and lacks of effective chemo targeted therapies. Cell lines animal models, even partially reflecting tumor characteristics, have limits to study ICC biology drug response. In this work, we created characterized a novel patient-derived xenograft (PDX) model Italian origin. Seventeen primary derived from patients were implanted into NOD (Non-Obese Diabetic)/Shi-SCID (severe combined immunodeficient) mice. To verify if...
Biliary tract carcinoma is a rare malignancy with multiple causes, which underlie the different genetic and molecular profiles. Cancer cell lines are affordable models, reflecting characteristics of tumor origin. They represent useful tools to identify targets for treatment. Here, we established characterized from biological, molecular, point view, an Italian intrahepatic cholangiocarcinoma line (ICC), MT-CHC01. MT-CHC01 cells were isolated tumor-derived xenograft. Immunophenotypical...
Intrahepatic cholangiocarcinoma (ICC) is one of the most lethal liver cancers. Late diagnosis and chemotherapy resistance contribute to scarce outfit poor survival. Resistance mechanisms are still poorly understood. Here, we established a Gemcitabine (GEM) resistant model, MT-CHC01R1.5 cell line, obtained by GEM gradual exposure (up 1.5 µM) sensitive counterpart, MT-CHC01. was irreversible, even at high doses. The in vitro vivo growth slower than MT-CHC01, no differences were highlighted...
Abstract Background and aims Cholangiocarcinoma (CCA) is a form of primary liver cancer with limited therapeutic options. Recently, stem cells (CSCs) have been proposed as driving force tumour initiation dissemination, thus representing crucial target. The protease inhibitor SerpinB3 (SB3) has identified in several malignancies including hepatocellular carcinoma. SB3 involved the early events hepatocarcinogenesis highly expressed hepatic progenitor mouse model cell activation. However, only...
ROS1 rearrangements have been detected in a variety of tumors and are considered as suitable targets anticancer therapies. We developed new, quick, specific, sensitive PCR test to screen for the FIG‐ROS1 fusion applied it series Italian patients with bile duct carcinoma (BTC). Formalin‐fixed, paraffin‐embedded tissues, derived from 65 BTC patients, six cell lines were analyzed by nested investigate prevalence previously reported fusion. The specificity sensitivity investigated positive...
Identification of culture conditions that support expansion or even long-term maintenance in vivo repopulating human hematopoietic stem cells is still a major challenge. Using combination FLT3 ligand (FL), Stem Cell Factor (SCF), Thrombopoietin (TPO) and Interleukin 6 (IL6), we cultured cord blood (CB) CD34+ for up to 12 weeks transplanted their progeny into sublethally irradiated NOD/SCID mice. Bone marrow engraftment was considered successful when recipients contained measurable numbers...
The association of anti-EGFR to gemcitabine and oxaliplatin (GEMOX) chemotherapy did not improve survival in biliary tract carcinoma (BTC) patients. Multiple mechanisms might be involved the resistance anti-EGFR. Here, we explored mutation profile EGFR extracellular domain (ECD), tyrosine kinase (TKD), its amplification status. mutational status exons 12, 18–21 was analyzed 57 tumors by Sanger sequencing. evaluated 37 Fluorescent In Situ Hybridization (FISH). Kaplan-Meier curves were...
Biliary tract carcinoma (BTC) has a poor prognosis due to limited treatment options. There is, therefore, an urgent need identify new targets and design innovative therapeutic approaches. Among potential candidate molecules, we evaluated the nonreceptor tyrosine kinase Src, observing promising antitumor effects of its small-molecule inhibitor saracatinib in BTC preclinical models. The presence active Src protein was investigated by immunohistochemistry 19 surgical samples from patients with...
Biliary tract carcinomas (BTC) are malignant tumors with limited therapeutic options. Clinical experiences anti-EGFR therapies have produced unsatisfactory results. The strategies of combined inhibition EGFR and MEK1/2 could be a promising option in BTC treatment. Preclinical activity Panitumumab Trametinib was tested vitro (EGI-1, MT-CHC01 WITT cells) vivo (xenograft) models different K-RAS mutational status. reduced MAPK phosphorylation wild type (WT) cells both mutated cells; EGI-1 also...
Abstract The HER2/c-ErbB-2 proto-oncogene is overexpressed in 25–30% of human breast cancers. We previously reported the c-ErbB-2 transcript mononuclear cells (MNC) from bone marrow (BM), peripheral blood (PB), and mobilized PB (MPB). Here, we describe extensively expression pattern mRNA protein normal adult hematopoietic tissue cord (CB)-derived cells. Quantitative reverse transcriptase-polymerase chain reaction shows that expressed at low levels if compared with epithelial cancer was...